Second, speed up the cultivation and cultivation of a number of large pharmaceutical enterprise groups, take enterprises as the core and rely on enterprises to vigorously develop China's biomedical industry, concentrate manpower, material resources and financial resources to achieve high-starting and high-standard biomedical development, avoid blooming everywhere and low-level redundant construction, realize the healthy and sustainable development of China's biomedical industry, and play a good role in industrial demonstration and driving.
Third, the state should learn from the advanced experience of Europe and America in biopharmaceuticals, accelerate the legislation of biopharmaceuticals in combination with China's national conditions, and continue to establish and improve a complete set of support policies and preferential support policies, including education, science and technology, research and development, new product protection, brand building and other biopharmaceuticals upstream and downstream industrial chains.
Fourth, encourage qualified enterprises to set up R&D centers overseas to meet international standards and master core technologies; Moderately tilt to enterprises that independently research and develop new products, and protect the enthusiasm of enterprises for independent research and development.
Fifth, it is suggested that the state give policy support to the development of innovative biopharmaceutical products.